摘要 跨界锂盐，万华打响化工巨头"抢滩"锂电发令枪 近日，大中矿业发布公告，公司拟与眉山高新区管委会、万华化学 ( 四川 ) 电池材料科技有限公司 签署三方《投资协议书》，合作投资建设 " 年产 20 万吨锂盐项目 " 。该项目拟分三期建设，其 中一期规划年产 3 万吨。 这一动作，是 2026 年开年以来全球化工巨头加码锂电产业的缩影。今年开年以来，除了频频出手 的万华化学，兴发集团、湖北宜化、云天化、巨化股份、多氟多、恒力石化、宝丰能源等多家化工 巨头，均在锂电布局领域落下关键棋子。 在锂电材料行业进入存量博弈、低端产能过剩、资源与技术成核心壁垒的新周期，化工巨头开始告 别过去粗放扩产模式，紧扣行业痛点与自身核心优势，走出了一条脉络清晰的布局之路。 从上游资源到终端材料，从国内扩产到海外布局，从现有技术迭代到下一代技术卡位，化工巨头们 在锂电赛道的触角全面铺开，形成了多点开花、梯队清晰的布局路线图。下图是 2026 年以来主要 化工巨头的锂电布局动态： | 企业阵营 代表企业 | | 2026 年开年以来核心布局动作 | | --- | --- | --- | | 国内化工 标杆 | 万华化学 | 1. ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Guangzhou Tinci Materials Technology Co., Ltd. 廣州天賜高新材料股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，不 會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據於香港公司註冊處處長註冊的本公司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士刊 發。 (a ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Guangzhou Tinci Materials Technology Co., Ltd. 廣州天賜高新材料股份有限公司 (the "Company") (A joint stock limited company incorp ...

证券研究报告 新宙邦 (300037 CH) 看好 6F 及添加剂贡献利润弹性 2026 年 3 月 23 日│中国内地 电力设备与新能源 25Q4 电解液盈利受益于原材料 6F 及添加剂涨价 25Q4 收入 30.23 亿元，同/环比+38.7%/+27.6%，归母净利 3.49 亿元，同/ 环比+45.2%/+32.2%，扣非净利 3.74 亿元，同/环比+53.4%/+50.2%。电解 液方面，我们推测 Q4 电解液盈利约 1 亿，出货量超 9 万吨，单吨净利超 1000 元，6F 及添加剂等涨价贡献超额盈利。氟化工方面，我们推测 Q4 氟 化工盈利超 2 亿，环比较为平稳。电容器化学品方面，我们推测公司 Q4 盈 利 0.5 亿，主要系 MLCC 化学品国产替代加速。公司 Q4 非经-0.26 亿，我 们推测主要系资产减值影响。 看好公司自产 6F 及添加剂贡献利润弹性 根据 Wind，截至 3 月 23 日，6F 价格为 11.1 万元/吨，较 12 月均价 18.0 万元/吨出现回落，主要系淡季效应下库存有所增加，而根据百川盈孚，截 至 3 月 23 日，六氟磷酸锂库存达 7290 吨，较 3 月 ...

Company and Industry Summary Company Overview - The company is involved in the production of electrolyte solutions, lithium iron phosphate (LFP) materials, and solid-state battery components, with a focus on the lithium battery supply chain. Key Points Industry and Market Position - The company maintains a market share of 38%-39% in the electrolyte segment, with a domestic production capacity of 280,000 tons nearly completed. Future growth will focus on overseas markets, with factories in Morocco and the USA expected to be operational by 2027-2028 [2][13]. - The projected market demand for hexafluorophosphate lithium (LiPF6) in 2026 is estimated to be between 330,000 to 350,000 tons, with an annual growth rate of 25%-35% [22]. Financial Performance - In 2025, the company achieved a revenue of 16.65 billion yuan, a year-on-year increase of 33%. Net profit attributable to the parent company was 1.362 billion yuan, up 181% [3]. - The electrolyte business was the main contributor to revenue growth, with sales exceeding 720,000 tons, a 45% increase year-on-year. The net profit per ton for electrolytes was over 2,000 yuan, doubling from 2024 [2][3]. Product Pricing and Profitability - The pricing of electrolytes is linked to lithium carbonate prices and is negotiated semi-annually, ensuring price stability [2][11]. - The expected net profit per ton for electrolytes in Q1 2026 is projected to rise to 6,000-7,000 yuan, reflecting a significant recovery in profitability [2][4]. Production and Capacity Expansion - The company plans to produce 1 million tons of electrolytes in 2026, with a target of 220,000 to 240,000 tons for lithium iron phosphate [2][21]. - A new 35,000-ton capacity for LiPF6 is being developed to prevent supply shortages in the second half of the year, as demand typically increases by 25%-30% [5]. Strategic Initiatives - The company is investing in a 1 million-ton iron source project to reduce the cost of lithium iron phosphate by 1,200-1,500 yuan per ton, leveraging by-products from its production processes [6]. - Solid-state battery initiatives are accelerating, with a pilot production line for lithium sulfide expected to be operational in H2 2026, targeting a gross margin of 20%-30% [2][10]. Challenges and Risks - The company anticipates that the LFP segment will continue to incur losses in the near term, although the losses are expected to narrow significantly in Q1 2026 [12]. - The company is cautious about the impact of fluctuating lithium carbonate prices on profitability, employing hedging strategies to mitigate risks [15]. Future Outlook - The company expects to see a turnaround in the LFP business by Q2 or H2 2026, driven by improved sales and pricing [12]. - The solid-state battery market's development will be closely monitored, with revenue contributions expected to align with industry progress [10][20]. Additional Insights - The company is exploring both recycling and mining for lithium resources to optimize costs, although specific details remain undisclosed [9]. - The company is also preparing for potential market entry into sodium battery electrolytes, which are expected to have similar pricing to traditional lithium-based electrolytes [22]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic positioning, financial performance, and future outlook within the lithium battery industry.

Financial Performance - In 2025, the company achieved a revenue of CNY 16.65 billion, representing a year-on-year growth of 33% [1] - The net profit attributable to shareholders was CNY 1.362 billion, with a significant increase of 181.43% [1] - The net profit after deducting non-recurring gains and losses was CNY 1.36 billion, up by 256.32% [1] - Basic earnings per share reached CNY 0.71 [1] Product Sales and Market Trends - The sales volume of the core product, electrolyte, exceeded 720,000 tons, marking a year-on-year growth of approximately 44% [1] - The annual sales of daily chemical materials surpassed 120,000 tons, reflecting a 10% increase compared to the previous year [1] - The overall revenue from the daily chemical materials business grew by 10.69% [1] Production Capacity and Resource Management - The company plans to add 35,000 tons of new production capacity for lithium hexafluorophosphate, with production expected to commence in the second half of 2026 [2] - The company is actively diversifying its lithium resource layout, including mining and recycling operations, to optimize raw material costs [2] - The production capacity for iron phosphate is currently at 300,000 tons, with efforts to improve operational efficiency and reduce costs [2] New Material Development - The current addition ratio of LiFSI in electrolytes is approximately 2%-2.5%, with expectations for an increase due to rising demand for high-performance formulations [3] - The company is in the kilogram-level trial production phase for sulfide solid electrolytes, with a pilot production line expected to be operational in Q3 2026 [3] - The company has established production capabilities for sodium-ion electrolytes and will gradually increase production based on market demand [3] International Expansion and IPO Progress - Overseas projects in Morocco and the USA have commenced, with completion expected between late 2027 and mid-2028 [4] - The company submitted its Hong Kong IPO application in September 2025 and is currently awaiting approval from the China Securities Regulatory Commission, with a typical review period of 6-9 months [5]

Group 1: Business Expansion and Strategy - The company entered the new energy sector based on its long-term chemical synthesis capabilities and commercial delivery abilities, achieving revenue breakthrough in this area in 2025 [1] - The company plans to continue strengthening its existing products, including LiFSI, cathode materials, and electrolyte products, with expectations for improved revenue and profit in 2026 [1] - The Malaysian base is planned to be built with an investment of $200 million, focusing on CDMO business for new products, with the first phase expected to be completed by the end of 2026 [2] Group 2: Pharmaceutical Business Development - The pharmaceutical business has shown steady growth, focusing on a large customer strategy and CDMO business model, with stable partnerships established with leading global pharmaceutical companies [3] - The company aims to expand its service offerings in the pharmaceutical sector, including small molecule CDMO, starting materials, and GMP intermediates, while also investing in emerging business areas such as peptide products and radioactive drugs [4][5] Group 3: Customer Dependency and Market Strategy - The company acknowledges a high customer concentration but emphasizes the importance of maintaining strong relationships with existing clients while actively seeking new customers across various sectors [7] - The company believes that focusing on existing customers and expanding the client base will foster mutual trust and long-term cooperation, ensuring sustainable business growth [7] Group 4: Financial Performance and Capital Expenditure - The company reported a net cash flow of approximately 900 million yuan from operating activities in the first three quarters of 2025, indicating sufficient self-funding for planned capital expenditures [8] - There are no immediate plans for capital operations centered on secondary market financing, with current capital expenditures focused on the construction of the coastal base and the Malaysian base [8] Group 5: Currency Exchange Impact - The company anticipates ongoing impacts from foreign exchange gains and losses due to significant USD revenues and the need for hedging strategies [9][10]

Group 1: Business Operations - The company's plant protection business has reached a bottom in inventory reduction, and future operations are expected to stabilize [1] - The company maintains a long-term partnership with clients, focusing on a CDMO business model for the production of advanced intermediates [1] - The company plans to invest $200 million in the construction of its Malaysia base, with the first phase expected to be completed by the end of 2026 [4] Group 2: New Energy Sector - The company primarily sells LiFSI, cathode materials, and electrolyte products, with plans to strengthen existing products in 2026 [3] - The lithium hexafluorophosphate product is undergoing technical improvements, with commercialization expected in 2026 [3] - The company aims to expand its new energy product range and market presence, leveraging its R&D and production capabilities [3] Group 3: Pharmaceutical Business - The pharmaceutical sector has shown steady growth, with a focus on large clients and CDMO business models [5] - The company is actively expanding its client base and developing new projects in the pharmaceutical sector [5] - The company is investing in R&D to enhance its technical capabilities, exploring new areas such as amino acids and peptides [6] Group 4: Client Dependency and Market Strategy - The company acknowledges a high client concentration but emphasizes the importance of maintaining strong relationships with existing clients while seeking new ones [6][7] - The company believes that focusing on existing clients and expanding the customer base fosters mutual trust and sustainable cooperation [7] Group 5: Financial Outlook and Capital Expenditure - The company has no immediate plans for capital operations in the secondary market, focusing instead on investments in its coastal and Malaysian bases [7] - The net cash flow from operating activities for the first three quarters of 2025 is approximately 1 billion, sufficient to support planned capital expenditures [7] - Exchange rate gains and losses are expected to continue affecting net profits, with significant USD revenues and hedging activities in place [7]

Company and Industry Summary Company Overview - The company focuses on agricultural protection and pharmaceuticals, covering four main sectors: agricultural protection, pharmaceuticals, functional chemicals, and equipment and engineering technology [1][1] - Established nearly 40 years ago, the company has 8 chemical production bases, 3 mechanical equipment production bases, and 3 R&D centers in China, along with one production base each in the UK and Malaysia [1][1] Key Points Agricultural Protection Sector - The agricultural protection CDMO (Contract Development and Manufacturing Organization) business has emerged from a low point and is now in a stable growth phase, serving major global agricultural protection companies [1][1] - Revenue in this sector is expected to slightly decline in 2023-2024 due to downstream inventory destocking [1][1] Pharmaceutical Sector - The company’s pharmaceutical CDMO business has seen a continuous increase in revenue share over the years, primarily serving the top twenty global pharmaceutical companies [2][2] - The pharmaceutical business is extending into the small nucleic acid drug raw material field, with rapid revenue growth anticipated due to increasing downstream customer demand [3][3] New Energy Sector - The company entered the new energy sector in 2021, with LiFSI (Lithium bis(fluorosulfonyl)imide) already commercialized [3][3] - The completion of technical upgrades for lithium hexafluorophosphate will enable the production of 200,000 tons of electrolyte, with 100,000 tons already constructed, contributing to new revenue streams [3][3] Financial Projections - Projected revenues for 2025-2027 are estimated at 6.312 billion, 7.373 billion, and 8.813 billion yuan, respectively, with net profits of 393 million, 513 million, and 617 million yuan [4][4] - Corresponding price-to-earnings ratios (PE) are expected to be 28.0, 21.5, and 17.8 times, respectively, with an initial coverage rating of "Accumulate" [4][4] Additional Insights - The company is replacing some old production capacity with new capacity for patented products, which is expected to enhance gross margins as the supply of off-patent products clears [2][2] - Strengthening relationships with partners is anticipated to lead to rapid growth in demand for patented products [2][2]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 78.00 [1][6]. Core Views - The company's Q4 performance slightly exceeded expectations, driven by increased demand for energy storage and battery chemicals, resulting in a revenue of RMB 9.639 billion for 2025, a year-on-year increase of 22.84% [1]. - The company anticipates further growth in the shipment of organic fluorine products and a gradual reduction in losses from Haidefu, with capacitors showing profit elasticity as new products ramp up [1]. - The report highlights the positive outlook for the 6F price recovery during peak seasons in 2026, which is expected to contribute to profitability [3]. - The company plans to pursue a Hong Kong listing to expand overseas production capacity, with significant investments in projects in Poland and Saudi Arabia [4]. Summary by Sections Q4 Performance - In Q4, the company reported revenue of RMB 3.023 billion, a quarter-on-quarter increase of 38.7% and a year-on-year increase of 27.6%, with net profit attributable to the parent company reaching RMB 350 million, up 45.5% year-on-year [2]. - The profitability from electrolyte products was approximately RMB 100 million, with shipments exceeding 90,000 tons and a net profit per ton exceeding RMB 1,000 [2]. Price Trends and Capacity - As of February 10, the price of 6F was RMB 130,000 per ton, down from an average of RMB 180,000 in December, attributed to seasonal inventory increases [3]. - The company has a 36,000-ton capacity for 6F and is expanding its production capabilities for lithium battery materials and semiconductor chemicals [4][5]. Financial Projections - The company has revised its revenue projections for 2025-2027, expecting net profits of RMB 10.98 billion, RMB 23.47 billion, and RMB 28.66 billion respectively, reflecting significant upward adjustments [6][12]. - The report anticipates a gross margin improvement for the electrolyte business, with expected margins of 12.4%, 21.1%, and 21.1% for 2025, 2026, and 2027 respectively [12][13]. Market Position and Valuation - The company is positioned favorably within the market, with a projected PE ratio of 25 times for 2026, reflecting its strong earnings potential compared to peers [6][14]. - The average PE for comparable companies is noted to be 20 times for 2026, indicating a competitive valuation for the company [14].